| |
All patients (n = 116)
|
C-maf-positive (n = 36)
|
C-maf-negative (n = 80)
|
p value
|
|---|
|
Therapy, n (%)
|
|
Bor
|
70 (60.3)
|
22 (61.1)
|
48 (60.0)
| |
|
Non-bor
|
46 (39.7)
|
14 (38.9)
|
32 (40.0)
|
0.910
|
|
Courses, n (%)
|
|
<3
|
44 (37.9)
|
11 (30.6)
|
33 (41.3)
| |
|
≥3
|
72 (62.1)
|
25 (69.4)
|
47 (58.7)
|
0.272
|
|
Response (ORR), n (%)
|
|
<PR
|
50 (46.9)
|
12 (43.6)
|
38 (48.3)
| |
|
≥PR
|
66 (53.1)
|
24 (56.4)
|
42 (51.7)
|
0.154
|
|
Response (VGPR), n (%)
|
|
<VGPR
|
63 (54.3)
|
22 (61.1)
|
41 (51.3)
| |
|
≥VGPR
|
53 (45.7)
|
14 (38.9)
|
39 (48.7)
|
0.324
|
|
Courses ≥3
|
N = 69
|
N = 24
|
N = 45
| |
|---|
|
Response (ORR), n (%)
|
|
<PR
|
7 (10.1)
|
3 (12.5)
|
4 (8.9)
| |
|
≥PR
|
62 (89.9)
|
21 (87.5)
|
41 (91.1)
|
0.641
|
|
Response (VGPR), n (%)
|
|
<VGPR
|
20 (29.0)
|
10 (41.7)
|
10 (22.2)
| |
|
≥VGPR
|
49 (71.0)
|
14 (58.3)
|
35 (77.8)
|
0.090
|
|
Bortezomib
|
N = 48
|
N = 16
|
N = 32
| |
|---|
|
Response (ORR), n (%)
|
|
<PR
|
4 (8.3)
|
1 (6.3)
|
3 (9.4)
| |
|
≥PR
|
44 (91.7)
|
15 (93.7)
|
29 (90.6)
|
0.712
|
|
Response (VGPR), n (%)
|
|
<VGPR
|
10 (20.8)
|
3 (18.8)
|
7 (21.9)
| |
|
≥VGPR
|
38 (79.2)
|
13 (81.2)
|
25 (78.1)
|
0.800
|
|
Non-bortezomib
|
N = 21
|
N = 8
|
N = 13
| |
|---|
|
Response (ORR), n (%)
|
|
<PR
|
3 (14.3)
|
2 (25.0)
|
1 (7.7)
| |
|
≥PR
|
18 (85.7)
|
6 (75.0)
|
12 (92.3)
|
0.278
|
|
Response (ORR), n (%)
|
|
<VGPR
|
10 (47.6)
|
7 (87.5)
|
3 (23.1)
| |
|
≥VGPR
|
11 (52.4)
|
1 (12.5)
|
10 (76.9)
|
0.003
|
-
Bor bortezomib, ORR overall response rate, VGPR very good partial response
